Document Detail


Difference between herpes simplex virus type 1 and type 2 neonatal encephalitis in neurological outcome.
MedLine Citation:
PMID:  2891886     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
24 infants consecutively treated with acyclovir or vidarabine for neonatal herpes simplex virus (HSV) encephalitis were followed up for 6 months to 3 years to assess neurological and developmental outcome. 15 patients had HSV-2 and 9 had HSV-1 encephalitis. Infants with HSV-2 encephalitis presented with a higher frequency of seizures, greater pleocytosis and protein concentrations in the cerebrospinal fluid, and more frequent evidence of structural damage on computerised tomographic scans of the brain than did those with HSV-1 encephalitis. 1 patient died. All 9 HSV-1 patients were normal at follow-up (mean 19.4 months) compared with only 4 (23%) of the 14 surviving HSV-2 infected infants (p = 0.003). Among infants with HSV-2 encephalitis, 50% became microcephalic; 57% had seizure disorders; 64% had ophthalmological defects; 64% had cerebral palsy; and 57% had mental retardation. Infants with neonatal HSV-1 encephalitis treated with systemic antiviral chemotherapy have excellent neurological outcomes; the neurological morbidity of those with HSV-2 encephalitis is still high.
Authors:
L Corey; R J Whitley; E F Stone; K Mohan
Related Documents :
22524536 - Neonatal outcome of the pregnancies associated with placental villous thrombosis - thro...
19391086 - The role of complement in neurodevelopmental impairment following neonatal hypoxic-isch...
21896576 - Tandem mass spectrometry findings at autopsy for detection of metabolic disease in infa...
2578926 - Prognostic value of the electroencephalogram in term and preterm infants following neon...
889146 - Compensatory responses of goat mothers to their impaired young.
7062166 - Clostridia isolated from the feces of infants during the first year of life.
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Lancet     Volume:  1     ISSN:  0140-6736     ISO Abbreviation:  Lancet     Publication Date:    1988 Jan 2-9
Date Detail:
Created Date:  1988-02-05     Completed Date:  1988-02-05     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  2985213R     Medline TA:  Lancet     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1-4     Citation Subset:  AIM; IM    
Affiliation:
Department of Laboratory Medicine, University of Washington, Seattle.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acyclovir / therapeutic use
Brain / physiopathology
Central Nervous System Diseases / cerebrospinal fluid,  etiology*,  radiography
Electroencephalography
Follow-Up Studies
Herpes Simplex / complications*,  drug therapy,  physiopathology,  radiography
Humans
Infant, Newborn
Vidarabine / therapeutic use
Grant Support
ID/Acronym/Agency:
AI-20381/AI/NIAID NIH HHS; N01 AI-62554/AI/NIAID NIH HHS
Chemical
Reg. No./Substance:
5536-17-4/Vidarabine; 59277-89-3/Acyclovir

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The guinea-pig isolated atrium as a model system for the central actions of selected CNS stimulant a...
Next Document:  Renal deposition of cytomegalovirus antigen in immunoglobulin-A nephropathy.